Archive: 20/09/2021
Adjuvant immunotherapy prolongs recurrence-free survival in resected stage II B/C melanoma
The first randomised phase III clinical trial in stage II melanoma has shown a 35% reduction in the risk of recurrence with adjuvant pembrolizumab compared with placebo. The late breaking results of the KEYNOTE-716 trial are presented ...
Sep 20, 2021
First-line CDK 4/6 inhibition shows overall survival benefit for metastatic breast cancer
Adding a CDK 4/6 inhibitor to first-line hormonal treatment prolongs survival by one year for postmenopausal women with hormone receptor (HR) positive, HER2 negative advanced breast cancer, according to late breaking results ...
Sep 20, 2021